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SIGNIFICANCE
This European multi-centre study investigated the occur-
rence, chronicity and intensity of itch in a large sample 
of outpatients with different skin diseases and healthy-
skin controls. In this study 54.3% of patients and 8% of 
healthy-skin controls had itch at the time of investigation. 
Chronic itch was reported by 36.9% of patients and 4.7% 
of healthy-skin controls. The mean itch intensity in pa-
tients was 5.5 ± 2.5 (on a scale from 0–10) compared with 
3.6 ± 2.3 in healthy-skin controls. Thus, itch is a very com-
mon, intense symptom among dermatological outpatients 
for which better specific therapies are needed. 
Itch is an unpleasant symptom, affecting many der-
matological patients. Studies investigating the occur-
rence and intensity of itch in dermatological patients 
often focus on a single skin disease and omit a control 
group with healthy skin. The aim of this multi-centre 
study was to assess the occurrence, chronicity and in-
tensity (visual analogue scale 0–10) of itch in patients 
with different skin diseases and healthy-skin controls. 
Out of 3,530 dermatological patients, 54.3% reported 
itch (mean ± standard deviation itch intensity 5.5 ± 2.5), 
while out of 1,094 healthy-skin controls 8% had itch 
(3.6 ± 2.3). Chronic itch was reported by 36.9% of the 
patients and 4.7% of the healthy-skin controls. Itch 
was most frequent (occurrence rates higher than 
80%) in patients with unclassified pruritus, prurigo 
and related conditions, atopic dermatitis and hand ec-
zema. However, many patients with psychodermato-
logical conditions and naevi also reported itch (occur-
rence rates higher than 19%). 
Key words: itch occurrence; itch intensity; itch chronicity; skin 
diseases; European perspective.
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The Global Burden of Disease Study 2010 (1) esti-mated that 33.7 million years lived with disability 
(YLD) are caused by skin and subcutaneous diseases. 
According to this study, which analysed data from 187 
countries, skin conditions represent “the fourth leading 
cause of nonfatal disease burden” (2), affecting 1.9 bil-
lion people at any time (2, 3). Itch, defined by Hafenreffer 
as “an unpleasant cutaneous sensation that provokes the 
desire to scratch” (4) has long been neglected and unre-
cognized, even though it represents a common symptom 
in patients with skin diseases (5–7). Thus, there is a need 
to better document itch in patients with skin disease in 
order to encourage the development of new treatments, 
allocate resources more appropriately and develop better 
care for patients with itch.
The distribution and burden of itch in dermatological 
patients is mainly known from single-centre studies (8, 
9) or studies focusing on a single skin disease (e.g. 10, 
11). Also, studies on the occurrence of itch are often 
uncontrolled (8–12). Recently, the European Society for 
Dermatology and Psychiatry (ESDaP) completed a large 
European observational cross-sectional multi-centre study 
to better document the psychological burden (i.e. anxiety 
and depression, negative life events and suicidal ideation) 
of patients with skin disease (13). In this study, patients 
Occurrence, Chronicity and Intensity of Itch in a Clinical Consecutive 
Sample of Patients with Skin Diseases: a Multi-centre Study in 13 
European Countries
Christina SCHUT1, Florence J. DALGARD2,3, Jon A. HALVORSEN4, Uwe GIELER5, Lars LIEN3,6, Lucia TOMAS ARAGONES7, 
Francoise POOT8, Gregor B. E. JEMEC9, Laurent MISERY10,11, Lajos KEMÉNY12, Francesca SAMPOGNA13, Henriët VAN 
MIDDENDORP14, Flora BALIEVA15, Dennis LINDER16, Jacek C. SZEPIETOWSKI17, Andrey LVOV18, Servando E. MARRON19, 
İlknur K. ALTUNAY20, Andrew Y. FINLAY21, Sam SALEK22 and Jörg KUPFER1
1Institute of Medical Psychology, Justus-Liebig-University, Gießen, Germany, 2Department of Dermatology and Venereology, Skåne University 
Hospital, Lund University, Malmö, Sweden, 3Innlandet Hospital Trust, National Center for Dual Diagnosis, Brumundal, Norway, 4Department 
of Dermatology, Oslo University Hospital, University of Oslo, Institute of Clinical Medicine, Oslo, Norway, 5Justus-Liebig-University Giessen, 
Giessen, Germany, 6Department of Public Health, Hedmark University College, Elverum, Norway, 7Department of Psychology, Faculty of 
Education University of Zaragoza, Aragon Health Sciences Institute (IACS), Zaragoza, Spain, 8Department of Dermatology, University 
Hospital Erasme, Brussels, Belgium, 9Department of Dermatology, Zealand University Hospital, Roskilde, Health Sciences Faculty, University 
of Copenhagen, Copenhagen, Denmark, 10Department of Dermatology, University Hospital of Brest, 11Laboratory of Neurosciences, University 
of Western Brittany, Brest, France, 12Department of Dermatology and Allergology, MTA-SZTE Dermatological Research Group, University of 
Szeged, Szeged, Hungary, 13Clinical Epidemiology Unit, Istituto Dermopatico dell’Immacolata (IDI)-IRCCS, Rome, Italy, 14Health, Medical and 
Neuropsychology unit, Faculty of Social and Behavioural Sciences, Leiden University, Leiden, The Netherlands, 15Department of Dermatology, 
Stavanger University Hospital, Stavanger, 16Section of Biostatistics, University of Oslo, Oslo, Norway, 17Department of Dermatology, Venereology 
and Allergology, Wrocław Medical University, Wroclaw, Poland, 18Department of Clinical Dermatology and Cosmetology, Moscow Scientific 
and Practical Center of Dermatovenereology and Cosmetology, Moscow, Russia, 19Dermatology Department, Royo Villanova Hospital, Aragon 
Health Sciences Institute (IACS), Zaragoza, Spain, 20Dermatology and Venereology Clinic, University of Health Sciences, Istanbul Sişli Hamidiye 
Etfal Health Training and Research Center, Şişli – Istanbul, Turkey, 21Dermatology and Academic Wound Healing, Division of Infection and 
Immunity, Cardiff University School of Medicine, College of Biomedical and Life Sciences, Cardiff, and 22School of Life and Medical Sciences, 
University of Hertfordshire, College Lane, Hatfield, UK
A
ct
aD
V
A
ct
aD
V
A
d
v
a
n
c
e
s 
in
 d
e
rm
a
to
lo
g
y
 a
n
d
 v
e
n
e
re
o
lo
g
y
A
c
ta
 D
e
rm
a
to
-V
e
n
e
re
o
lo
g
ic
a
C. Schut et al.2
www.medicaljournals.se/acta
with skin diseases from 15 out-patient dermatological 
clinics in 13 different countries (i.e. Belgium, Denmark, 
France, Germany, Hungary, Italy (2 study centres), the 
Netherlands, Norway (2 study centres), Poland, Russia, 
Spain, Turkey, the UK) were included. The large database 
generated by this study also enables exploration of the 
symptom itch in the group of all skin patients, as well as 
the assessment of the distribution of itch in different skin 
diseases. Moreover, the data allows the comparison of 
the occurrence, chronicity and intensity of itch between 
patients with skin diseases and healthy-skin controls. 
The aims of the study are: (i) to describe the occurrence 
of current (acute) and chronic itch (itch lasting longer 
than 6 weeks) as well as the intensity of current itch in 
skin patients compared with healthy-skin controls; (ii) 
to describe the occurrence of current (acute) and chronic 
itch (itch lasting longer than 6 weeks) as well as the in-
tensity of current itch among patients with different skin 
diseases; (iii) to determine whether skin patients with 
itch differ from skin patients without itch and healthy-
skin controls regarding age, sex and the occurrence of 
physical comorbidities.
MATERIALS AND METHODS 
Study design
A secondary analysis of data that have already been published 
(13) was conducted. However, it should be emphasized that data 
on the occurrence, chronicity and intensity of itch from this data-
base have not been published previously. The investigation was 
an observational cross-sectional multicentre study with 15 sites 
in 13 European countries (13). Out-patients in secondary and ter-
tiary care were recruited from 15 dermatological clinics between 
November 2011 and February 2013. The study protocol was that, 
at each clinic, consecutive patients were invited to participate in 
the study until 250 patients were included (for the exact numbers 
recruited in each country, see (13)). The participation rate was 
79.9% (13). The inclusion criteria were age at least 18 years and 
being able to read and write the local language. Experiencing se-
vere psychosis or receiving psychiatric treatment were exclusion 
criteria. A control group of 1,359 participants was recruited via 
advertisements among hospital employees at the same institution, 
but not from the dermatology department. Persons in the control-
group were subjectively skin-healthy and regarded themselves not 
in need of consulting a dermatologist due to any skin condition. 
Controls who reported having a skin condition were excluded. 
Each participant completed the same questionnaires. In skin 
patients, the dermatological diagnosis was made by a dermatolo-
gist. Usually one, but in some cases two or more, dermatological 
diagnoses were recorded. If there were doubts as to whether a 
skin disease was present (e.g. no diagnosis, no flares or no itch) 
the patient was not included in the study. The diagnoses were al-
located to 27 categories adapted from the Lambeth study (14). The 
decision about what category the diagnosis should be allocated to 
was made by 3 dermatologists who are experts in the field of itch 
research (FD; UG; JAH). The category “unclassified pruritus” was 
chosen in those cases where patients visited the clinic due to itch, 
but no explicit diagnosis had yet been given. 
The presence of other physical conditions (cardiovascular 
diseases, chronic respiratory diseases, diabetes, rheumatological 
diseases and others) was identified by asking the patient or by 
reviewing the patient’s file. The controls were not examined and 
information on physical comorbidities was self-reported (for 
details see (13)). 
Questionnaires
Itch and its characteristics were assessed with the following items: 
“Does your skin itch now?” (yes/no), if yes “For how long?” 
(under 6 weeks/over 6 weeks), whereby itch lasting for less than 
6 weeks represents acute itch, while itch lasting for longer than 
6 weeks represents chronic itch (15)) and “How intense is your 
itching?” with responses given on a visual analogue scale from 
0 (“none”) to 10 (“worst imaginable”). The VAS was used to 
measure itch intensity, because it has been shown to be a reliable 
and valid tool to measure the subjective symptom itch (16). In 
addition, self-reported socio-demographic data, such as age, sex, 
socio-economic status and marital status, were recorded. 
Ethics
The protocol for the European study was approved by the Re-
gional Committee for Medical Research Ethics in Norway REK 
2011/1087. Local ethical approval was obtained, where necessary, 
in the other countries. The study was conducted in accordance with 
the Declaration of Helsinki and ICH/EU good clinical practice.
Statistical analyses
Data were entered into a database at each site and sent to the Sta-
tistical Center in Giessen, Germany. The data were consolidated 
into a single file. SPSS version 22 software (IBM Corp, released 
2013) was used to process and analyse the data. To characterize 
the sample, we report numbers, percentages with 95% confidence 
interval (CI), or mean values with standard deviation (SD). To 
compare patients and healthy-skin controls, we used t-tests for 
continuous variables and χ2 tests for dichotomous or categorical 
variables. We describe the occurrence of physical comorbidities 
with number and percentages with 95% CI. Multivariate logistic 
regression analyses were conducted to study the associations 
between the occurrence, chronicity and groups, adjusted for sex 
and age. Odds ratios (ORs) were calculated using the regression 
coefficients β from the regression models. The exponential of 
the coefficient represents the OR. Because of the great number 
of regression analyses, the p-values were corrected using the 
Bonferroni-correction according to Holm (17), as done in a re-
cently published study (18).
RESULTS 
Subjects 
A total of 3,635 patients from 15 different study centres 
and 1,359 healthy-skin controls took part in the study 
(also see (13)). Of these, 3,530 patients (97.1% of all exa-
mined patients) and 1,094 healthy-skin controls (80.5% 
of all healthy-skin controls) responded to the question 
on the presence of itch. This group of 4,624 subjects 
constituted the sample in the present study. Regarding 
the analyses of 27 different skin diseases, patients with 
2 or more dermatological diagnoses (441 subjects) were 
excluded, thus 3,089 patients (having one dermatological 
diagnosis each) were included in these analyses.
Sociodemographic characteristics of patients and 
healthy-skin controls are presented in Table I. There 
were no significant differences between patients with and 
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without itch regarding age or sex (p > 0.05). There were 
fewer females in the group of patients compared with 
the group of healthy-skin controls (p < 0.001). The group 
of dermatological patients was significantly older than 
the healthy-skin control group (p < 0.001). In addition, 
the socio-economic status varied between patients with 
itch and healthy-skin controls (p < 0.1). Also, the marital 
status differed between groups (p < 0.05). Moreover, 
physical comorbidities were significantly more common 
in patients with itch compared with both patients without 
itch or healthy-skin controls (also see Table I). Of the 
patients with itch, 31.5% (95% CI 29.5–33.4) had at least 
one physical comorbidity, while only 15.7% (95% CI 
13.5–17.7) of the healthy-skin control group had at least 
1 physical comorbidity. The OR for comorbidities was 
1.76 (95% CI 1.43–2.18) in patients with itch compared 
with healthy-skin controls (adjusted for age and sex). 
Itch occurrence, chronicity and intensity in skin patients 
compared with healthy-skin controls
In total, 54.3% (1,917 out of 3,530) of the patients with 
skin diseases reported that they currently had itch, com-
pared with 8.0% (88 out of 1,094) of the healthy-skin 
controls. The OR of reporting itch when having a skin 
disease was 13.64 (95% CI 10.82–17.20) compared 
with healthy-skin controls. Chronic itch was reported by 
36.9% of the patients and 4.7% of the healthy-skin con-
trols. The overall mean ± SD itch intensity was 2.96 ± 3.3 
in patients and 0.29 ± 1.18 in healthy-skin controls. The 
mean ± SD intensity of itch among patients reporting itch 
was 5.50 ± 2.51 (Table II). 
Itch occurrence and chronicity in patients with different 
skin diseases
The occurrence rates of current and chronic itch among 
the different patient groups are shown in Table III. The 
occurrence of itch was highest in patients with unclassi-
fied pruritus (96.2%), prurigo (88.9%), atopic dermatitis 
(86.0%), hand eczema (82.3%), other eczemas (77.7%) 
and urticaria (75.9%). The patient groups with the highest 
occurrence of chronic itch were patients with unclassified 
pruritus (78.0%), prurigo and related conditions (72.2%), 
atopic dermatitis (66.7%) and other eczemas (56.5%). 
In patients with hand eczema the occurrence of chronic 
Table I. Sociodemographic characteristics and physical comorbidities (excluding skin diseases) of patients with itch, patients without 
itch and healthy-skin controls
Patients with itch
(n = 1,917/3,530)
Patients without 
itch
(n = 1,613/3,530)
Healthy-skin 
controls
(n = 1,094)
Test patients 
with itch 
vs. patients 
without itch
Test patients 
with itch vs. 
healthy-skin 
controls
Test patients 
without itch vs. 
healthy-skin 
controls
Sex, n (%)
   Female 1,077 (56.3) 907 (56.5) 705 (64.6) χ2(1)=0.02 χ2(1)=19.80*** χ2(1)=17.51***
   Male 837 (43.7) 698 (43.5) 387 (35.4)
Age, years, mean ± SD 47.2 ± 17.5 46.7 ± 18.3 40.5 ± 13.3 t(3300)=0.93 t(2744.6)=11.00*** t(2648.1)=10.11***
Socio-economic status, n (%)
   Low 403 (21.4) 227 (14.3) 176 (16.2) χ2(2)=28.80*** χ2(2)=12.16** χ2(2)=2.08
   Middle 1,325 (70.2) 1,215 (76.6) 809 (74.3)
   High 159 (8.4) 144 (9.1) 104 (9.6)
Marital status, n (%)
   Single 442 (25.3) 413 (27.4) 293 (26.8) χ2(3)=19.71*** χ2(3)=33.25*** χ2(3)=8.70*
   Married 1007 (57.7) 920 (61.0) 679 (62.2)
   Separated 163 (9.3) 106 (7.0) 92 (8.4)
   Widowed 132 (7.6) 69 (4.6) 28 (2.6)
Physical comorbidities 
(excluding skin diseases), 
overall 
n (%), 95% CI) MD n (%), 95% CI MD n (%), 95% CI MD OR (95% CI) OR (95% CI) OR (95% CI)
573 (31.5), 29.5–33.4 100 385 (25.0), 
22.7–27.1
71 164 (15.7), 
13.5–17.7
47 1.48 (1.25–1.75) 1.76 (1.43–2.18) 1.17 (0.93–1.46)
*p < 0.05, **p < 0.01, ***p < 0.001 (retrieved by t-tests).
Data from patients with one (n = 3,089) and two or more (n = 441) dermatological diagnoses. Healthy-skin controls were persons both with and without itch.
SD: standard deviation; MD: missing data; OR: odds ratio (adjusted for age and sex); 95% CI: 95% confidence interval.
Table II. Occurrence, chronicity and intensity of itch in dermatological patients in 13 European countries and in healthy-skin controls as 
well as the associations (OR) between the occurrence/chronicity of itch in patients and the occurrence/chronicity of itch in healthy-skin 
controls
Patients
(n = 3,530)
Healthy-skin controls
(n = 1,094)
Patients/healthy-skin 
controls
n/valid cases (%), 95% CI Missing/out of n/valid cases (%), 95% CI Missing/out of OR (95% CI)
Occurrence 1,917/3,530 (54.3), 52.5–55.9 88/1,094 (8.0), 6.6–9.8 13.6 (10.8–17.2)
Chronicity
   Overall 1,225/3,316 (36.9), 35.3–38.6 214/3,530 51/1,075 (4.7), 3.5–6.0 19/1,094 11.4 (8.5–15.3)
   In those with itch 1,225/1,703 (71.9), 69.9–74.1 214/1,917 51/69 (73.9), 62.9–84.5 19/88 0.8 (0.5–1.5)
Intensity Mean (SD) Mean (SD) B (95% CI)
   Overall 2.96 (3.30) 44/ 3530 0.29 (1.18) 1/1094 2.67 (2.47–2.88)
   In those with itch 5.50 (2.51) 44/1917 3.64 (2.29) 1/88 1.84 (1.30–2.39)
   In those with chronic itch 5.92 (2.41) 22/1225 4.08 (2.37) 0/51 1.80 (1.11–2.48)
Data constitutes patients with 1 (n = 3,089) and 2 or more (n = 441) dermatological diagnoses. 
OR: odd ratio (adjusted for sex and age); CI: confidence interval; SD: standard deviation; B: regression coefficient.
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itch was very high, with 53% of patients experiencing 
itch lasting longer than 6 weeks. 
In all skin patients the occurrence rates of current itch 
were at least doubly high as in the group of healthy-skin 
controls. Even in patients with naevi, 19.9% of patients 
reported having current itch compared with 8% of the 
healthy-skin controls. Also, the number of patients with 
psychodermatological conditions who reported having 
itch was very high: 54.5% reported having current itch 
and 40% reported having chronic itch.
Itch intensity in patients with different skin diseases
The intensity of itch among the different patient groups 
is given in Table SI1. 
The highest mean intensity of itch was found in the 
following diagnostic groups: unclassified pruritus (VAS 
score: 7.03), prurigo (VAS score: 6.15), atopic dermatitis 
(VAS score: 5.35), hand eczema (VAS score: 4.73) and 
urticaria (VAS score: 4.73). 
The itch intensity among those reporting itch was high-
est in unclassified pruritus (VAS score: 7.31), prurigo 
(VAS score: 6.97), psychodermatological conditions 
(VAS score: 6.33), urticaria (VAS score: 6.31), atopic 
dermatitis (VAS score: 6.22) and hidradenitis suppurativa 
(VAS score: 6.03). 
While the mean itch intensity was very low in healthy-
skin controls (VAS score: 0.29), it was above 1 in all 
patient groups, except for patients with naevi (VAS 
score: 0.77) and patients with benign skin tumours (VAS 
score: 0.98). 
DISCUSSION 
This is the first large multi-centre study in Europe com-
paring the occurrence, chronicity and intensity of itch 
between patients with skin diseases and healthy-skin 
controls. Approximately half of the patients visiting a 
dermatological outpatient clinic in Europe reported that 
they experience itch. About 37% of them reported having 
itch lasting longer than 6 weeks. 
The occurrence of current itch in dermatological 
patients (54%) reported in this study is higher than the 
occurrence found previously in a German study, in which 
334 patients from a single dermatological practice had 
a point prevalence of current itch of 36.2% (8). It is hy-
pothesized that the difference may be explained by the 
high proportion of neoplasms (n = 88) in the previous 
study as only 23.9% of neoplasms were accompanied 
by pruritus. In the current study, patients with psoriasis 
Table III. Occurrence and chronicity of itch in patients experiencing 1 of 27 different skin diseases and healthy-skin controls. Associations 
(OR) between the occurrence of itch in patients and occurrence of itch in healthy-skin controls, adjusted for age and sex
Diagnostic categories (n)
Occurrence 
n (%), 95% CI
Patients/healthy-skin 
controls
OR (95% CI)
Occurrence of chronic itch 
overalla
Occurrence of chronic itch in 
those with itchb
Missing/
out of n (%), 95% CI
Missing/
out of n (%), 95% CI
Patients overall (3,089) 1,664 (53.9), 52.0–55.6   13.5 (10.7–17.0)* 172/3,089 1,065 (36.5), 34.9–38.3 172/1664 1,065 (71.4), 68.9–73.7
Unclassified pruritus (53)   51 (96.2) 90.4–100 285.4 (67.2-1212.4)* 3/53 39 (78.0), 66.0-88.2 3/51 39 (81.3), 70.2-92.0
Prurigo and related conditions (18)   16 (88.9), 72.2–100.0 85.9 (18.9–389.4)* 0/18 13 (72.2), 50.0–93.3 0/16 13 (81.3), 61.1–100
Atopic dermatitis (150) 129 (86.0), 79.9–91.2 67.0 (40.0–112.0)* 6/150 96 (66.7), 58.6–74.5 6/129 96 (78.0), 70.9–85.2
Hand eczema (124) 102 (82.3), 75.6–88.9 52.7 (31.5–88.0)* 7/124 62 (53.0), 44.3–62.5 7/102 62 (65.3), 55.6–75.0
Other eczemas (197) 153 (77.7), 71.5–83.4 39.4 (26.1–59.6)* 11/197 105 (56.5), 49.5–63.7 11/153 105 (73.9), 66.4–80.6
Urticaria (54)   41 (75.9), 63.3–86.3 37.0 (19.0–71.9)* 5/54 21 (42.9), 30.0–56.2 5/41 21 (58.3), 42.9–73.2
Seborrhoeic dermatitis (54)   40 (74.1), 60.8–85.5 32.9 (17.2–63.0)* 2/54 19 (36.5), 22.5–50.0 2/40 19 (50.0), 34.8–66.0
Psoriasis (567) 399 (70.4), 66.4–74.2 29.82 (22.02–40.39)* 37/567 263 (49.6), 45.0–53.8 37/399 263 (72.7), 68.0–77.0
Bullous diseases (62)   40 (64.5), 53.2–76.2 25.4 (13.4–48.0)* 2/62 23 (38.3), 25.9–50.8 2/40 23 (60.5), 45.0–76.6
Psychodermatological conditions (22)   12 (54.5), 33.4–76.1 13.8 (5.7–33.2)* 2/22   8 (40.0), 20.0–61.9 2/12   8 (80.0), 50.0–100
Granuloma annulare (11)     6 (54.5), 25.0–81.8 12.8 (3.8–43.6)* 0/11   5 (45.5), 18.2–75.0 0/6   5 (83.3), 50.0–100
Connective tissue disorders (79)   41 (51.9), 40.0–62.2 13.2 (7.9–22.3)* 0/79 30 (38.0), 28.0–48.1 0/41 30 (73.2), 58.3–86.8
Infections of the skin (205) 103 (50.2), 43.3–57.0 11.7 (8.2–16.8)* 13/205 59 (30.7), 24.3–37.6 13/103 59 (65.6), 55.7–75.3
Lichen planus (36)   18 (50.0), 33.3–66.7 11.54 (5.6–23.8)* 1/36 14 (40.0), 23.5–55.3 1/18 14 (82.4), 61.1–100
Leg ulcer (103)   48 (46.6), 36.9–56.2 9.0 (5.4–15.3)* 5/103 36 (36.7), 27.5–46.7 5/48 36 (83.7), 71.4–93.7
Hidradenitis suppurativa (40)   18 (45.0), 29.3–61.0 9.8 (5.0–19.0)* 3/40 10 (27.0: 13.2; 42.1 3/18 10 (66.7), 41.2–87.5
Others (286) 126 (44.1), 38.2–50.0 8.6 (6.2–11.9)* 17/286 70 (26.0), 20.6–31.4 17/126 70 (64.2), 54.8–72.9
Rosacea (54)   23 (42.6), 29.1–55.4 8.9 (4.9–16.1)* 1/54 11 (20.8), 10.4–32.0 1/23 11 (50.0), 29.2–71.9)
Other hair conditions (62)   25 (40.3), 27.4–51.8 8.1 (4.6–14.2)* 6/62 15 (26.8), 15.8–38.2 6/25 15 (78.9), 58.6–95.0)
Alopecia areata (22)     8 (36.4), 17.4–57.1 6.6 (2.7–16.2)* 1/22   7 (33.3), 13.6–55.0 1/8   7 (100), 100–100
Non-melanoma skin cancer (304) 105 (34.4), 28.9–39.7 6.1 (3.9–9.5)* 26/304 64 (23.0), 18.1–28.0 26/105 64 (81.0), 72.2–89.3
Acne (187)   57 (30.5), 24.2–37.3 5.6 (3.5–8.9)* 6/187 42 (23.2), 17.3–29.5 6/57 42 (82.4), 70.6–92.5
Hyperhidrosis (11)     3 (27.3), 0–54.5 4.4 (1.1–17.2)* 0/11   2 (18.2), 0–45.5 0/3   2 (66.7), 0–100
Vitiligo (23)     6 (26.1), 8.7–43.5 4.3 (1.6–11.5)* 0/23   2 (8.7), 0–21.7 0/6   2 (33.3), 0–75.0
Benign skin tumours (131)   31 (23.7), 16.8–30.9 3.7 (2.3–5.9)* 3/131 14 (10.9), 5.4–16.8 3/31 14 (50.0), 31.4–66.7
Malignant melanoma (57)   13 (22.8), 12.3–33.9 3.3 (1.6–6.6)* 2/57   9 (16.4), 6.9–26.4 2/13   9 (81.8), 57.1–100
Nevi (141)   28 (19.9), 13.0–26.6 2.9 (1.8–4.6)* 10/141 12 (9.2), 4.8–15.0 10/28 12 (66.7), 43.8–88.9
Healthy–skin controls (1094)   88 (8.0), 6.6–9.8 1 19/1,094 51 (4.7), 3.5–6.1 19/88 51 (73.9), 62.7–84.4
Data consists of patients with 1 dermatological diagnosis, patients with 2 and more dermatological diseases were excluded from these analyses; n = 3,089. The conditions 
are ranked according to itch occurrences. (Exception: data of the group of all patients (patients overall) are presented first and data of healthy-skin controls are presented 
last). *Occurrence rates significantly differed between patients and healthy-skin controls (p < 0.05; alpha-corrected after Holm). aOccurrence of chronicity in the whole 
group. bOccurrence of chronicity only among those who report itch. OR: odds ratio; CI: confidence interval.
1https://www.medicaljournals.se/acta/content/abstract/10.2340/00015555-3040
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constituted the largest group of patients with 567 cases, 
70.4% of whom reported itch. Moreover, in contrast to 
the previous study, in our study in 13 out of 27 diagnostic 
groups the number of patients with pruritus was greater 
than the number of patients without pruritus. In the 
previous study, more than half of the patients reported 
pruritus in only 2 (atopic eczema and dermatitis) out of 
9 diagnostic groups (8). 
A study of 1,428 dermatology outpatients from Turkey 
demonstrated an occurrence of chronic itch of 30.9% 
(9), which is in line with our finding that 37% of the 
dermatological skin patients experienced chronic itch. 
A Dutch study of 826 skin patients assessed in a general 
practice setting found that 53.3% of the assessed patients 
reported a mean itch intensity >2 on a VAS during the 
last 4 weeks (19). We speculate that the difference may 
be explained by the differing time spans studied, i.e. a 
shorter duration (4 weeks) over which itch was assessed 
in the Dutch study. 
The occurrence of itch among controls in our study 
(8.0%) is similar to the occurrence that has been reported 
for the general population previously (8.4% and 6.5%) 
in 2 large studies in Denmark and Norway (12, 20). Re-
garding chronic itch, we found that 4.7% of the controls 
reported having chronic itch, a much smaller percentage 
than those reported in 2 German population-based studies 
(13.5% or 15.4%, respectively; (21, 22)). One has to keep 
in mind, however, that our controls cannot be regarded as 
representative for the general population, as our controls 
did not have any skin condition. 
In the current study itch was most prevalent in patients 
diagnosed with unclassified pruritus, prurigo, atopic der-
matitis, hand eczema, other eczemas and urticaria. The 
occurrence and chronicity of itch across different skin 
diseases has already been reported, but mainly in patients 
with psoriasis and eczema: In a large US questionnaire-
based study including 17,425 respondents, itch was 
reported by 79% of the psoriasis patients (11). In atopic 
eczema, the occurrence of daily itching was 87% and 91% 
in 2 studies in which 100 or 304 patients were investigated 
(10, 23). Moreover, it was found that in chronic idiopathic 
urticaria, itch occurred in 68% of patients on a daily basis 
(24). In a recent study investigating 78 patients with lichen 
planus, 69.2% of the patients reported experiencing itch 
during the examination (25). In a questionnaire-based 
study assessing 1,541 adult patients with vitiligo, 35% 
of the patients reported itch or burning (26). In patients 
with hidradenitis suppurativa, itch occurred in 57.3% 
of the patients (27). These studies in most cases report 
occurrence rates that are comparable to ours. However, 
many of them are single-centre studies often including 
small numbers of patients. In contrast, our study had a 
large sample size and the simultaneous inclusion of many 
patient groups, some not previously reported. 
With the current study, we were able to show that the 
occurrence of itch is also quite high in diseases usually 
not characterized by itch, e.g. infections of the skin, leg 
ulcers, naevi, skin cancer, rosacea and alopecia areata. 
In these skin diseases, the occurrence of itch was at least 
2.88 times higher than in healthy-skin controls. 
The mean itch intensities found in the current study 
in patients with atopic dermatitis, urticaria, psoriasis or 
seborrheic dermatitis were all lower than the ones found 
in a large US study (28). The difference in itch intensities 
between these studies is not surprising as the US patients 
were highly selected patients with very intense itch due 
to their visit to a specialized tertiary itch centre.
The strengths of our study are the large sample size, 
inclusion of a large spectrum of skin diseases with 
some in which the epidemiology of itch has not been 
reported previously, the standardized assessment of the 
occurrence, chronicity and intensity of itch as recently 
recommended (29) and the continental scope of the data 
reflecting a wide range of cultural and socio-economic 
settings. 
The weaknesses of the study include a possible selec-
tion bias, as the clinics where patients were recruited are 
predominantly academic settings. Moreover, it would 
have been preferable to validate self-reported diagnoses 
by doctors. Persons in the control group categorized 
themselves as skin healthy without being seen by a der-
matologist. Thus, it is possible that persons were included 
in the control group, who regarded themselves as skin 
healthy, but actually had some kind of skin disease. It 
is also of note that all persons in the control group were 
part of the working population as they were recruited 
from hospital stuff, while we do not know how many 
of the skin patients were working. Moreover, the study 
design did not allow us to distinguish between untreated 
patients and those who had already received treatment 
for their skin disease. Comparing these 2 groups in fu-
ture studies would allow assessment as to whether the 
relationship between itch and physical comorbidities 
was greater in patients experiencing itch for a long time 
than in patients that had just received the diagnosis. Also, 
we did not further differentiate between different kinds 
of bullous diseases. As there are apparently large diffe-
rences in itch between bullous pemphigoid, dermatitis 
herpetiformis and pemphigus, these differences should 
be assessed prospectively in future studies. In addition, 
almost one-third (31.5%) of patients with itch had at 
least one physical comorbidity. Since itch is a symptom 
of some systemic diseases (e.g. renal failure, lymphoma, 
endocrine disease) and can be a side-effect of many 
drugs used to treat physical diseases (30), it would also 
be interesting to differentiate between itching and non-
itching comorbidities in future studies. Some groups of 
patients were small: 8 groups of patients had less than 
50 participants, which led to big confidence intervals in 
the analysis. However, we still chose to report the occur-
rence, chronicity and intensity of itch in these patients 
in order to not exclude any patients. 
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For a thorough discussion of the strength and weaknes-
ses of the design, see Dalgard et al. (13). 
In conclusion, this multi-centre study, which included 
dermatological patients and healthy-skin controls, em-
phasizes that itch is a common symptom among dermato-
logical out-patients with many different skin diseases. It 
thus highlights the need for better itch-specific therapies 
and tailored management strategies. 
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Supplementary material to article by C. Schut et al. ”Occurrence, Chronicity and Intensity of Itch in a Clinical Consecutive Sample of Patients 
with Skin Diseases: a Multi-centre Study in 13 European Countries”
Table SI. Intensity of itch in patients with 1 of 27 different skin diseases and healthy-skin controls
Diagnostic categories (n when itch=yes)
Intensity overalla
Intensity in those with 
itchb
Intensity in those with 
chronic itchc
n Mean (SD) n Mean (SD) n Mean (SD)
Patients overall (1,664) 3,052 2.94 (3.30) 1,627 5.51 (2.49) 1,046 5.92 (2.39)
Unclassified pruritus (51) 52 7.03 (2.70) 50 7.31 (2.34) 39 7.46 (2.21)
Prurigo/related conditions (16) 17 6.15 (2.98) 15 6.97 (2.01) 12 7.00 (2.27)
Atopic dermatitis (129) 150 5.35 (3.07) 129 6.22 (2.34) 96 6.58 (2.24)
Hand eczema (102) 122 4.73 (3.02) 100 5.78 (2.26) 61 6.30 (2.06)
Other eczemas (154) 195 4.66 (3.32) 151 6.02 (2.45) 105 6.12 (2.51)
Urticaria (41) 52 4.73 (3.68) 39 6.31 (2.83) 20 6.90 (2.69)
Seborrhoeic dermatitis (40) 54 3.95 (2.75) 40 5.34 (1.65) 19 5.37 (1.46)
Psoriasis (399) 563 3.91 (3.29) 395 5.57 (2.48) 261 5.99 (2.37)
Bullous diseases (40) 60 3.46 (3.21) 38 5.46 (2.29) 21 5.52 (2.52)
Psychodermatological conditions (12) 22 3.45 (3.65) 12 6.33 (2.35)   8 6.63 (2.50)
Granuloma annulare (6) 10 2.10 (2.73)   5 4.20 (2.39)   4 4.50 (2.65)
Connective tissue disorders (42) 79 3.04 (3.44) 41 5.85 (2.48) 30 5.93 (2.36)
Infections of the skin (103) 202 2.74 (3.24) 100 5.53 (2.40) 57 5.97 (2.07)
Lichen planus (18) 34 2.66 (3.19) 16 5.65 (2.10) 12 6.28 (1.71)
Leg ulcer (48) 102 2.75 (3.49) 47 5.96 (2.67) 35 6.49 (2.51)
Hidradenitis suppurativa (18)   39 2.63 (3.31) 17 6.03 (2.07) 10 6.35 (2.26)
Others (126) 282 2.25 (3.07) 122 5.21 (2.53) 69 5.48 (2.38)
Rosacea (23) 54 1.90 (2.59) 23 4.46 (2.06) 11 4.91 (2.34)
Other hair conditions (25) 61 1.55 (2.56) 24 3.94 (2.69) 15 4.77 (2.91)
Alopecia areata (8) 21 1.76 (2.91)   7 5.29 (2.56)   7 5.29 (2.56)
Non melanoma skin cancer (105) 297 1.29 (2.27) 98 3.91 (2.29) 60 4.94 (2.27)
Acne (57) 187 1.41 (2.44) 57 4.63 (2.15) 42 4.76 (2.02
Hyperhidrosis (3) 11 1.55 (2.88)   3 5.67 (2.52)   2 7.00 (1.41)
Vitiligo (6) 23 1.26 (2.43)   6 4.83 (2.32)   2 4.50 (2.12)
Benign skin tumours (31) 131 0.98 (2.04) 31 4.13 (2.15) 14 3.68 (2.09)
Malignant melanoma (13)   57 1.32 (2.75) 13 5.81 (2.66)   9 6.22 (2.64)
Naevi (28) 140 0.77 (1.87) 27 3.98 (2.33) 12 4.29 (2.53)
Healthy-skin controls (88) 1,093 0.29 (1.18) 87 3.64 (2.29) 51 4.08 (2.37)
Data from patients with one dermatological diagnosis, patients with 2 and more dermatological diseases were excluded from 
these analyses. Intensity measured by a visual analogue scale (VAS) ranging from 0 to 10. The conditions are ranked according 
to itch occurrences. (Exception: data of the group of all patients (patients overall) are presented first and data of healthy-skin 
controls are presented last). 
aIntensity in the whole group. bIntensity among those who report itch. cIntensity among those who report chronic itch.
SD: standard deviation. 
